Why Attend eDiscovery
The litigation and regulatory investigations that are emerging as a result of the financial services crisis demand reliable e-discovery processes and IT systems for identifying, collecting and preserving potentially relevant evidence. It is more important than ever for the stakeholders in the highly regulated financial industry to understand what increased oversight means, initiate the best coping/response plan, and evaluate how the FRE 502 impacts their eDiscovery process. Legal IQ’s 4th E-Discovery Pharmaceutical and Biotech Industry Event will put its focus on industry specific challenges and practical solutions, join me this coming February to share your expertise and best practices.
Past Attending Companies Include
- Abbott Laboratories
- Allergan
- Amgen
- AstraZeneca
- Bayer
- BioMérieux Inc
- Blue Cross of Northeastern Pennsylvania
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cardinal Health Inc.
- Cell Therapeutics, Inc.
- Cephalon Inc
- Dechert LLP
- Department Of Veterans Affairs
- Dickstein Shapiro LLP
- District Court of New Jersey
- Elan Drug Delivery Inc
- Elan Pharmaceuticals Inc.
- Eli Lilly & Company
- Emisphere Technologies Inc
- Forest Laboratories, Inc
- Genetech
- Genzyme Corporation
- GlaxoSmithKline, Inc.
- Intuitive Surgical
- Johnson & Johnson
|
- Meda Pharmaceuticals
- Medtronic
- Merck & Company
- Morgan, Lewis & Brockius LLP
- NJ Dept of Environmental Protection
- Novartis Pharmaceutical Corp.
- Novo Nordisk
- Orrick, Herrington & Sutcliffe LLP
- Pfizer Inc
- Purdue Pharma LP
- Roche Diagnostics Operations Inc
- RTI Biologics, Inc.
- Safe-BioPharma Association
- Sanofi-Aventis
- Schering-Plough
- Sepracor
- Sourthern District Court of New York
- State of Texas
- Taro Pharmaceuticals
- Teva Pharmaceuticals
- Tolerx Inc
- United States District Court
- US Attorney's Office
- US Securities and Exchange Commission
- Wyeth Pharmaceuticals
|
